MaxCyte, Inc. (LON:MXCT - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Friday . The company traded as low as GBX 158 ($2.13) and last traded at GBX 168 ($2.26), with a volume of 16582 shares traded. The stock had previously closed at GBX 165.50 ($2.23).
MaxCyte Price Performance
The stock has a market capitalization of £221.77 million, a P/E ratio of -6.16 and a beta of 1.13. The business has a fifty day simple moving average of GBX 191.01 and a 200-day simple moving average of GBX 271.16. The company has a debt-to-equity ratio of 8.59, a quick ratio of 14.38 and a current ratio of 9.81.
MaxCyte Company Profile
(
Get Free Report)
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Further Reading
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
